Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$83.28

0.34 (0.41%)

, ABBV

AbbVie

$93.96

1 (1.08%)

04:55
11/08/17
11/08
04:55
11/08/17
04:55

American College of Rheumatology City to hold annual meeting

Annual Meeting of ACR/ARHP 2017 is being held in San Diego on November 3-8.

LLY

Eli Lilly

$83.28

0.34 (0.41%)

ABBV

AbbVie

$93.96

1 (1.08%)

AMGN

Amgen

$173.48

2.68 (1.57%)

BIIB

Biogen

$313.57

-1.9 (-0.60%)

CELG

Celgene

$102.33

0.69 (0.68%)

FLXN

Flexion

$23.71

0.24 (1.02%)

DGX

Quest Diagnostics

$92.66

-0.49 (-0.53%)

RHHBY

Roche

$28.95

-0.27 (-0.92%)

GILD

Gilead

$73.21

0.83 (1.15%)

GSK

GlaxoSmithKline

$35.82

-0.32 (-0.89%)

HZNP

Horizon Pharma

$14.00

-0.35 (-2.44%)

IRWD

Ironwood

$15.13

-0.1 (-0.66%)

MNK

Mallinckrodt

$20.11

-11.07 (-35.50%)

MCK

McKesson

$136.93

1.72 (1.27%)

NAVB

Navidea

$0.43

-0.0016 (-0.37%)

NVS

Novartis

$82.39

-1.11 (-1.33%)

OPHM

OraPharma

PFE

Pfizer

$35.36

0.04 (0.11%)

QDEL

Quidel

$37.66

-1.04 (-2.69%)

REGN

Regeneron

$404.39

-2.24 (-0.55%)

SNY

Sanofi

$45.58

-0.49 (-1.06%)

ZYNE

Zynerba

$10.83

-0.36 (-3.22%)

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 11

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

  • 14

    Dec

  • 23

    Dec

  • 03

    Feb

  • 12

    Feb

  • 23

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

LLY Eli Lilly
$83.28

0.34 (0.41%)

10/10/17
10/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HSBC (HSBC) downgraded to Underperform from Neutral at Credit Suisse with analyst Sanjay Jain citing valuation. 2. Jabil Circuit (JBL) downgraded to Sell from Neutral at Goldman Sachs with analyst Mark Delaney saying street expectations, which assume Jabil's earnings grow double digits year-over-year for both of the next two years, are overly optimistic. 3. Carlyle Group (CG) downgraded to Neutral from Buy at Citi with analyst William Katz citing valuation with the shares up 60% year-to-date. 4. Eli Lilly (LLY) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying the valuation looks full with the shares up 13% since mid-August. 5. Ralph Lauren (RL) downgraded to Sell from Hold at Miller Tabak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
PIPR
10/24/17
NO CHANGE
Target $107
PIPR
Overweight
Eli Lilly Humalog fears overblown, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss attributes Eli Lilly's (LLY) post-earnings decline to further anxiety around price competition in the U.S. diabetes segment after the company said on its earnings call that it will not challenge Sanofi's (SNY) biosimilar for Humalog. However, he sees these concerns as substantially overdone, pointing to the 39% year-over-year growth reported in Q3 for the diabetes franchise, and view today's pullback as a clear buying opportunity. Purkiss keeps an Overweight rating on Eli Lilly and raised his price target on the stock to $107 from $105.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.
10/18/17
SBSH
10/18/17
UPGRADE
Target $72
SBSH
Buy
Merck upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded Merck (MRK) to Buy and raised his price target for the shares to $72 from $65. The healthcare giant closed yesterday down 12c to $63.22. While Merck's non-Keytruda business continues to erode, the market is undervaluing both the ultimate patient derived xenograft market size and Merck's likely market share with Keytruda, Baum tells investors in a research note. The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B. The analyst prefers Eli Lilly (LLY), Bristol-Myers (BMY) and Merck among the U.S. pharmaceutical majors. He also downgraded Roche (RHHBY) this morning to Neutral.
ABBV AbbVie
$93.96

1 (1.08%)

10/27/17
PIPR
10/27/17
NO CHANGE
Target $115
PIPR
Overweight
AbbVie price target raised to $115 from $102 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss raised his price target for AbbVie to $115 saying he continues to see "substantial" upside in the shares following the company's Q3 results. The analyst, citing AbbVie's growing hematology/oncology business and a "rejuvenated" hepatitis c virus franchise, reiterates an Overweight rating on the shares.
11/07/17
GSCO
11/07/17
NO CHANGE
Target $105
GSCO
Conviction Buy
AbbVie remains most attractive name within biopharma, says Goldman
Goldman analyst Jami Rubin said AbbVie is still the most attractively positioned name within biopharma with a growth profile in the top tier of its peer group and a valuation at the lowest tier, "leaving a huge gap" to unlock further value. Rubin met with management who reiterated it expects to grow through Humira's erosion curve and highlighted confidence in the pipeline where consensus only reflects a fraction of AbbVie's long-term forecasts. The analyst rates shares a Conviction Buy with a $105 price target.
10/30/17
RHCO
10/30/17
NO CHANGE
Target $105
RHCO
Buy
AbbVie price target raised to $105 from $95 at SunTrust
SunTrust analyst John Boris raised his price target on Abbvie to $105 and maintained his Buy rating. Boris is modeling an $80M increase in sales of Humira as well as the Mavyret global HCV rollout and the pre-launch plans for its Elagolix, Rova-T, UPAD and RISA pipeline. The analyst also notes that Abbvie CEO is delivering on his long-term strategic plan, with best-in-class growth rates.
10/30/17
LEER
10/30/17
NO CHANGE
Target $107
LEER
Outperform
AbbVie new long-term guidance could give stock 'legs to run,' says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie reported Q3 financial results that were in-line with expectations. The biggest surprise from management's update was the confidence in their late stage immunology and oncology assets, forecasting that at least three of these clinical stage products will achieve 2025 revenue of $5B or greater, he contends. The analyst reiterates an Outperform rating on the stock, while lowering his price target on the shares to $107 from $107, and says he still anticipates "significant upside" emerging from late stage pipeline programs being de-risked in the next 1-3 quarters.
AMGN Amgen
$173.48

2.68 (1.57%)

10/30/17
PIPR
10/30/17
NO CHANGE
PIPR
Overweight
Piper says Europe may be real battleground for biosimilar Soliris threat
Piper Jaffray analyst Christopher Raymond noted that Amgen (AMGN) recently gained EU authorization to conduct a 40 patient, cross-over design Phase 3 trial comparing their biosimilar eculizumab to Alexion's (ALXN) Soliris. He also found evidence of Amgen's active opposition to Alexion's IP extension efforts in Europe. Raymond said many "breathed a sigh of relief" that Soliris' U.S. position on Soliris appears safe out to 2027, but he said these new signs make it appear the real battleground may be Europe. He keeps an Overweight rating on Alexion, stating that "while noise from this challenge won't go away," he thinks the company is well equipped to run its defense.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold at Argus on secular slowdown in sales of top drugs
As reported earlier, Argus analyst David Toung downgraded Amgen to Hold from Buy, noting a "secular" slowdown in sales of the company's top three products - Enbrel, Neulasta and Aranesp. Toung says the sales of growth prospects Prolia, Kyprolis and Repatha are not yet large enough to offset the declines in the three established drugs which face generic competition after losing patent protection. The analyst notes that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal challenges.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold from Buy at Argus
10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
BIIB Biogen
$313.57

-1.9 (-0.60%)

10/25/17
10/25/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3M (MMM) upgraded to Neutral from Sell at Goldman Sachs with analyst Joe Ritchie saying amid "strong" organic growth and an underlevered balance sheet, the case to sell the shares is now "less apparent." 2. PulteGroup (PHM) upgraded to Neutral from Underperform at Mizuho. 3. Biogen (BIIB) upgraded to Outperform from Market Perform at BMO Capital with analyst M. Ian Somaiya saying risks to the multiple sclerosis franchise and Spinraza are getting "quickly priced in" following yesterday's post-earnings selloff. 4. Synopsys (SNPS) upgraded to Top Pick from Outperform at RBC Capital with analyst Mitch Steves saying the company's margin profile should improve over the next 2-3 years given the company's exposure to the "Internet of Things," Artificial Intelligence and Semiconductor content in automobiles. 5. Capital One (COF) upgraded to Neutral from Underperform at Wedbush with analyst Henry Coffey saying the company continues to report loan quality metrics in both its U.S. consumer credit card portfolio and commercial lending business that are consistent with his cautious outlook, but beating earnings per share estimates based on non-credit related items. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/27/17
10/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. IBM (IBM) initiated with a Buy at Pivotal Research. 2. Alder Biopharmaceuticals (ALDR) initiated with a Buy at Canaccord. 3. Biogen (BIIB) initiated with a Hold at Canaccord. 4. Okta (OKTA) initiated with a Buy at SunTrust. 5. Carvana (CVNA) initiated with a Market Perform at Barrington. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/30/17
OPCO
10/30/17
NO CHANGE
Target $166
OPCO
Outperform
Oppenheimer raises Celgene target to $168 on 'highly positive' study
Oppenheimer analyst Leah Rush Cann raised her price 12- to 18-month price target for shares of Celgene (CELG) to $168 from $163 citing the "highly positive" Radiance trial results. The stock in midday trading is up 2% to $100.00. The study, evaluating the efficacy and safety of Ozanimod versus a first-line treatment, Biogen's (BIIB) Avonex, in patients with relapsing multiple sclerosis met primary and secondary endpoints with "highly positive and significant results," and serious adverse events were reported to be low and similar across all treatment arms, Cann tells investors in a research note. The analyst is now including "modest" estimated sales of Ozanimod in multiple sclerosis starting in 2019. She keeps an Outperform rating on Celgene.
10/27/17
ADAM
10/27/17
INITIATION
Target $340
ADAM
Hold
Biogen initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Biogen with a Hold rating. He said the core MS franchise gives him pause due to potential headwinds from generics and brands, which are underappreciated by investors. Kulkarni has a $340 price target on Biogen shares.
CELG Celgene
$102.33

0.69 (0.68%)

11/01/17
CANT
11/01/17
NO CHANGE
Target $58
CANT
Neutral
Cantor ups bluebird target to $58, maintains Underweight rating
Cantor Fitzgerald analyst Elemer Piros raised his price target for bluebird bio (BLUE) to $58 from $39 following the introduction of multiple myeloma into his model. While no new data were introduced, partner Celgene (CELG) is planning to move the program to the pivotal setting, Piros tells investors in a research note. The analyst, however, remains "only cautiously optimistic" of the company's eventual success in sickle cell disease. The American Society of Hematology abstracts today provided an early glimpse at the modified drug manufacturing process for sickle cell disease, the analyst notes.
10/30/17
FBCO
10/30/17
NO CHANGE
Target $128
FBCO
Outperform
Celgene ozanimod data 'solid,' expectations high on safety, says Credit Suisse
Credit Suisse analyst Alethia Young says that while ozanimod full data was "very strong," Celgene set the expectations high for the full data and so she does not expect the stock to move on this data. The analyst sees increased importance for ozanimod's success to help diversify the portfolio beyond Revlimid. Young reiterates an Outperform rating and $128 price target on the shares.
10/27/17
WELS
10/27/17
NO CHANGE
WELS
Underperform
Wells says Celgene comments about psoriasis market 'concerning' for Valeant
Wells Fargo analyst David Maris noted that Celgene (CELG) described the U.S. psoriasis market as challenging, which he believes has a "concerning" read through for Valeant (VRX) and its recent launch of the psoriasis drug Siliq. Based on Celgene's commentary and recent IMS data, he is concerned that his 2017 and 2018 forecasts for Siliq may be "substantially too high," but Maris said he will wait to hear Valeant's commentary with its upcoming earnings report before making any changes. He maintains an Underperform rating on Valeant shares.
FLXN Flexion
$23.71

0.24 (1.02%)

10/24/17
BMOC
10/24/17
NO CHANGE
BMOC
Outperform
Flexion well prepared ahead of Zilretta launch, says BMO Capital
BMO Capital analyst Gary Nachman said in a note to investors last night that after meeting with Flexion management he came away impressed with their level of preparedness for the commercial launch of Zilretta. He attributes the stock weakness since the drug's approval to shorter-term trading dynamics until management can demonstrate execution, but he thinks expectations have been lowered and are becoming much more achievable. Nachman keeps an Outperform rating on Flexion shares.
10/10/17
JANY
10/10/17
NO CHANGE
Target $38
JANY
Buy
Flexion price target raised to $38 from $35 at Janney Capital
Janney Capital analyst Ken Trbovich said nothing in the label for Zilretta has changed his view about its long-term potential, noting that he sees the drug as a major advance in the treatment of osteoarthritis knee pain. Trbovich said Flexion management confirmed that its $570 wholesale acquisition cost is expected to translate to net revenue of about $500/ injection, consistent with his expectations. He raised his fair value estimate for Flexion shares to $38 from $35 and keeps a Buy rating on the stock.
10/27/17
RBCM
10/27/17
NO CHANGE
RBCM
Flexion shares at compelling entry point after 34% pullback, says RBC Capital
RBC Capital analyst Randall Stanicky reiterated an Outperform rating and $44 price target on Flexion, saying he sees the 34% pullback in Flexion shares this month ahead of the Zilretta launch as short term, given the company's solid funding of about $12 cash per share, its thematic positioning as an opioid alternative, and its inherent strategic value.
10/30/17
WELS
10/30/17
NO CHANGE
Target $39
WELS
Outperform
Survey suggests Flexion Zilretta will be 'a hit,' says Wells Fargo
Wells Fargo analyst David Maris notes that while Flexion shares have declined in recent weeks following the approval of Zilretta and its subsequent equity offering, he believes this decline is mainly due to lack of near-term news flow, not a change in fundamentals. Citing a survey of 25 orthopedic surgeons, the analyst says results are very consistent with previous physician surveys and doctor interviews, indicating "significant potential" for Zilretta. If Zilretta reaches 37% penetration in OA knee, as the survey results suggest, it would generate more than $1B in revenue, he contends. Maris reiterates an Outperform rating and $39 price target on the shares.
DGX Quest Diagnostics
$92.66

-0.49 (-0.53%)

10/17/17
CHLM
10/17/17
NO CHANGE
Target $100
CHLM
Hold
Quest Diagnostics price target lowered to $100 from $110 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Quest Diagnostics to $100 from $110 to account for hurricane-related disruption in Florida, Texas, and Puerto Rico based on its disclosure in late September. The analyst views the weather-related impact as a one-time event. He reiterates a Hold rating on the shares.
10/10/17
10/10/17
DOWNGRADE
Target $113

Buy
Quest Diagnostics removed from Conviction Buy List at Goldman Sachs
As previously reported, Goldman removed Quest Diagnostics from the Conviction Buy List and lowered its price target to $113 from $121. Analyst Isaac Ro thinks share gains associated with PAMA reimbursement cuts could take time to manifest as competitors debate long-term strategies. The analyst maintains a Buy rating on Quest given its a pure-play on lab testing, margin expansion opportunities, and shareholder friendly capital deployment.
10/12/17
WELS
10/12/17
UPGRADE
Target $175
WELS
Outperform
LabCorp resumed with an Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of LabCorp and upgraded the shares to Outperform with a $175 price target. The analyst sees LabCorp outperforming Quest Diagnostics (DGX) due to its "slightly" higher revenue growth profile and diversification as well as more attractive valuation.
10/12/17
WELS
10/12/17
INITIATION
Target $88
WELS
Market Perform
Quest Diagnostics resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of Quest Diagnostics with a Market Perform rating and $88 price target. The rating is unchanged from his firm's prior coverage.
RHHBY Roche
$28.95

-0.27 (-0.92%)

10/30/17
LEHM
10/30/17
DOWNGRADE
Target $62
LEHM
Equal Weight
Merck downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Merck (MRK) to Equal Weight and cut his price target for the shares to $62 from $72. The healthcare company closed Friday down 6% to $58.24. The analyst sees less upside potential for Keytruda sales in lung cancer with the withdraw of the KN-021G filing in Europe for front-line non-small cell lung cancer and delays to the Phase 3 KN-189 trial from adding overall survival as a co-primary endpoint. Merck may have to compete in bidding for growth assets for a "revenue bridge," Meacham tells investors in a research note following Merck's Q3 results. He also believes lung cancer data in late 2017/early 2018 from both Bristol-Myers Squibb (BMY) and Roche (RHHBY) could further weigh on Merck's investor sentiment.
10/31/17
JEFF
10/31/17
UPGRADE
Target $55
JEFF
Hold
Merck upgraded to Hold from Underperform at Jefferies
Jefferies analyst Jeffrey Holford upgraded Merck (MRK) to Hold and bumped up his price target for the shares to $55 from $54. The healthcare company closed yesterday down 6% to $54.71. The sharp decline in the shares over the past few trading days has removed much of the downside, Holford tells investors in a research note partially titled "Keytruda Bulls Neutralized." Merck remains the analyst's least preferred stock. He believes Roche (RHHBY) may benefit most from the Keytruda delays.
10/24/17
BREN
10/24/17
DOWNGRADE
BREN
Hold
Roche downgraded to Hold from Buy at Berenberg
Berenberg analyst Alistair Campbell downgraded Roche to Hold and lowered his price target for the shares to CHF 260 from CHF 273. The analyst sees the company's earnings growth slowing to the slow single digits over the next five years as biosimilar competition ramps.
10/24/17
10/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) was downgraded to Hold from Buy at Stifel and to Underperform from Perform at Oppenheimer. 2. Whirlpool (WHR) was downgraded to Sector Perform from Top Pick at RBC Capital and to Neutral from Buy at BofA/Merrill. 3. Roche (RHHBY) downgraded to Hold from Buy at Berenberg with analyst Alistair Campbell saying he sees the company's earnings growth slowing to the slow single digits over the next five years as biosimilar competition ramps. 4. United Continental (UAL) downgraded to Neutral from Overweight at Atlantic Equities with the firm's analyst saying earnings initiatives do not appear to be performing to plan and he is "very skeptical" of United's ability to close the margin gap with Delta (DAL). 5. Hanesbrands (HBI) downgraded to Perform from Outperform at Oppenheimer with analyst Anna Andreeva saying while she remains a fan of "Brands over Retailers" framework, and Hanesbrands has profitability cushions, negative organics domestically take away earnings upside bull case. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$73.21

0.83 (1.15%)

10/19/17
WBLR
10/19/17
NO CHANGE
WBLR
Outperform
Gilead CAR-T priced below expectations, says William Blair
William Blair analyst Y. Katherine Xu says the $373,000 price for Gilead Sciences' CAR-T product Yescarta is below her estimate of $425,000. The analyst lowered her peak sales estimate for Yescarta to $3.3B from $4.1B but notes the change does not materially affect her fair value estimate of Gilead shares, which she keeps at $87. Xu keeps an Outperform rating on Gilead.
10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
10/19/17
JEFF
10/19/17
NO CHANGE
JEFF
Hold
Gilead CAR-T approval comes early, pricing in-line, says Jefferies
Jefferies analyst Michael Yee says approval of Gilead Sciences' CAR-T Yescarta came one month ahead of expectations and the list price of $373,000 is in-line with expectations. The analyst expects the launch to be strong over the course of the year and estimates 2018 revenue above consensus in the $200M-$250M range. Yee keeps a Hold rating on Gilead, saying hepatitis C virus numbers remain too high and need to come down.
10/19/17
MSCO
10/19/17
NO CHANGE
MSCO
Equal Weight
Gilead faces patent battle with Juno over Yescarta, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Juno (JUNO) has filed a lawsuit in the Central District of California alleging that Gilead's (GILD) newly-approved Yescarta infringes a patent that is exclusively licensed to Juno from Memorial Sloan Kettering. The analyst, who said he would expect a modest royalty to Juno, sees this fight as a source of potential upside to Juno but not as a major headwind for Gilead. Harrison, who said in a separate note to investors that Yescarta's pricing and timeline appear in-line with expectations, keeps Equal Weight ratings on both Gilead and Juno.
GSK GlaxoSmithKline
$35.82

-0.32 (-0.89%)

09/08/17
MSCO
09/08/17
DOWNGRADE
MSCO
Underweight
GlaxoSmithKline downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded GlaxoSmithKline to Underweight saying its 2020 roadmap appears "challenging" given capital allocation constraints and low R&D optionality.
10/26/17
BOFA
10/26/17
DOWNGRADE
BOFA
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Graham Parry downgraded GlaxoSmithKline to Neutral due to increasing headwinds including 2018 margin pressure and consensus reductions from Advair generic erosion, HIV franchise risk from competition, and dividend uncertainty.
10/26/17
10/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill with analyst Graham Parry citing increasing headwinds including 2018 margin pressure and consensus reductions from Advair generic erosion, HIV franchise risk from competition, and dividend uncertainty. 2. Global Eagle (ENT) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying Ernst & Young declining to stand for re-appointment increases the chances of an annual filing delay and a potential subsequent delisting by Nasdaq. The analyst cut his price target for the shares to $2 from $3. 3. trivago (TRVG) downgraded to Underperform from Neutral at BofA/Merrill and to Neutral from Buy at Guggenheim. 4. Lear (LEA) downgraded to Neutral from Buy at Guggenheim. 5. L Brands (LB) downgraded to Neutral from Buy at Buckingham with analyst Kelly Halsor saying she believes L Brands' margin recovery is facing headwinds in both brands resulting in incremental pricing investments and promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HZNP Horizon Pharma
$14.00

-0.35 (-2.44%)

11/07/17
JEFF
11/07/17
NO CHANGE
Target $21
JEFF
Buy
Horizon Pharma price target raised to $21 from $16 at Jefferies
Jefferies analyst David Steinberg raised his price target for Horizon Pharma to $21 following the company's "solid" Q3 results. The analyst increased his revenue expectations to reflect higher sales of Krystexxa and added pipeline program teprotumumab to his model with a peak sales estimate of over $500M. Steinberg keeps a Buy rating on the shares.
09/28/17
GSCO
09/28/17
INITIATION
GSCO
Buy
Horizon Pharma initiated with a Buy at Goldman Sachs
Goldman analyst Dana Flanders initiated Horizon Pharma with a Buy and a $16 price target. Flanders said shares have underperformed due to the company's high level of M&A activity but expects strong cash flow generation and capital allocation towards orphan and specialty assets to drive long-term topline growth and margins.
10/05/17
JEFF
10/05/17
NO CHANGE
Target $16
JEFF
Buy
Horizon's largest potential drug not included in Street models, says Jefferies
Following the "strong" recent Phase 2 results, clinicians believe Horizon Pharma's teprotumumab could become the thyroid eye disease therapy of choice, Jefferies analyst David Steinberg tells investors in a research note titled "'Tepro' Could Be HZNP's Largest Product - but the Street Doesn't Value It." The drug, however, is largely excluded from Street models, the analyst adds. He believes that teprotumumab, if approved, could conservatively research peak sales of $500M, implying 23% upside to the current valuation. Further, if the drug proves to be truly disease-modifying, peak revenue could reach $1.5B, implying 68% upside, Steinberg writes. He feels current therapies for TED are "very limited" and that the drug development pipeline is "lackluster." Steinberg has a Buy rating on Horizon Pharma with a $16 price target.
09/27/17
JMPS
09/27/17
NO CHANGE
Target $22
JMPS
Outperform
Horizon Pharma has other patents to protect Ravicti, says JMP Securities
After Lupin won its challenge to Horizon Pharma's '559 patent for Ravicti, JMP Securities analyst Donald Ellis noted that Horizon will appeal the IPR decision, which could take 12-18 months. Also, Ravicti has the recently issued '197 patent, which is unaffected by the '559 decision and extends until 2030, he tells investors. Ellis reiterates his Outperform rating and $22 price target on Horizon Pharma shares, which slid about 2% to $11.95 yesterday following the USPTO ruling.
IRWD Ironwood
$15.13

-0.1 (-0.66%)

08/17/17
JPMS
08/17/17
NO CHANGE
JPMS
JPMorgan lists top SMID Biotechnology picks following Q2 results
Analysts at JPMorgan continue think selectively remains important in the small-to-mid cap Biotechnology space. The analysts listed their favorite ideas in "five key buckets." Amicus (FOLD) is the top long-term pick, Ironwood (IRWD) is the top pick among relative underperformers, Otonomy (OTIC) is the top play for a clinical/binary event, Sarepta (SRPT) is the name to take advantage of the recent share weakness, and Ignyta (RXDX) is the "underfollowed/undervalued" favorite, according to JPMorgan's Biotech team.
07/21/17
JPMS
07/21/17
DOWNGRADE
Target $19
JPMS
Neutral
Ironwood downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Ironwood Pharmaceuticals to Neutral with a slightly reduced price target of $19. While Linzess remains in a strong position, it could take before "meaningful value creation" from the company's pipeline is realized, given that late-stage trial results are likely multi-years out, Rama tells investors in a research note. The analyst would look to become more constructive on a pullback.
07/21/17
WELS
07/21/17
NO CHANGE
Target $19
WELS
Outperform
Ironwood 8% selloff yesterday 'appropriate,' says Wells Fargo
Wells Fargo analyst David Maris views Ironwood Pharmaceuticals' Phase IIb data evaluating IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease as "OK, but impressive." While the trial met is primary endpoint, Ironwood released data only for the highest dose, 1500 mg, and not the 1000 mg or 500 mg doses, Maris tells investors in a researhc note. Further, he notes that heartburn severity in IW-3718 patients was 12 percentage points below the PPI alone. Maris believes yesterday's 8% share decline "is appropriate" and he dropped his price target for the shares to $19 from $21.50. The analyst keeps an Outperform rating on Ironwood.
07/20/17
MZHO
07/20/17
NO CHANGE
MZHO
Ironwood weakness a buying opportunity, says Mizuho
MNK Mallinckrodt
$20.11

-11.07 (-35.50%)

11/07/17
DBAB
11/07/17
DOWNGRADE
DBAB
Hold
Mallinckrodt downgraded to Hold from Buy at Deutsche Bank
11/03/17
HCWC
11/03/17
DOWNGRADE
Target $1.75
HCWC
Neutral
Ocera Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Ocera Therapeutics (OCRX) to Neutral saying he does not expect competing takeover bids to rival Mallinckrodt's (MNK). The analyst has a $1.75 price target for the shares.
11/07/17
BMOC
11/07/17
NO CHANGE
Target $38
BMOC
Outperform
BMO slashes Mallinckrodt target, calls today's selloff 'exaggerated'
BMO Capital analyst Gary Nachman cut his price target for Mallinckrodt shares to $38 from $65 following this morning's Q3 earnings report. The "surprising and disappointing news" in the quarter pertained to Acthar, which missed expectations amid a spike in number of prescriptions written going unfilled, Nachman tells investors in a post-earnings research note. The analyst sees this issue, despite management's confidence, persisting for several quarters. Nachman, however, keeps an Outperform rating on Mallinckrodt. He believes the selloff in shares today is "exaggerated." The stock in afternoon trading is down 34%, or $10.50, to $20.68.
11/07/17
DBAB
11/07/17
DOWNGRADE
Target $28
DBAB
Hold
Deutsche downgrades Mallinckrodt with Acthar prescriptions going unfilled
Deutsche Bank analyst Gregg Gilbert earlier today downgraded Mallinckrodt to Hold from Buy and cut his price target for the shares to $28 from $44. The stock in late afternoon trading is down 34% to $20.56 following the pharmaceutical company's Q3 earnings report. Acthar sales were surprisingly affected in the quarter by an increasing number of prescriptions going unfilled, Gilbert tells investors in a research note. He lowered his sales growth assumptions for Mallinckrodt's largest product to below management's outlook, citing uncertainty around how quickly this negative trend will reverse.
MCK McKesson
$136.93

1.72 (1.27%)

10/27/17
JEFF
10/27/17
NO CHANGE
JEFF
Amazon licenses likely related to medical equipment, says Jefferies
News of Amazon.com's (AMZN) receipt of wholesale pharmacy licenses drove a sell-off yesterday in pharma supply chain stocks, Jefferies analyst Brian Tanquilut tells investors in a research note. Shares of AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) fell yesterday in late afternoon trading. The analyst says that while the news strengthened investor fears about Amazon's entry into drug retailing, his due diligence indicates the licenses Amazon obtained are likely associated with its sale and distribution of medical equipment rather than prescription drugs. Tanquilut, however, recognizes that Amazon fears will overhang over prescription supply chain stocks in the near-term. He believes the impact to distributors from Amazon's professional medical device sales and distribution business remains difficult to assess.
11/01/17
NEED
11/01/17
NO CHANGE
Target $173
NEED
Buy
McKesson price target lowered to $173 from $178 at Needham
Needham analyst Kevin Caliendo lowered his price target on McKesson (MCK) to $173 despite a solid quarter, saying the positive results were overshadowed by Amazon (AMZN) receiving wholesale pharmacy licenses in 12 states. The analyst notes a 15% reversal in the stock price from its post-earnings high, also attributing the price target drop to changing investor sentiment and a a lowered terminal growth rate of 1%.
10/10/17
10/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Prudential (PRU) upgraded to Buy from Neutral at FBR Capital. 2. RBS (RBS) was upgraded to Neutral from Sell at Citi and to Neutral from Underperform at Credit Suisse. 3. Palo Alto Networks (PANW) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying he sees building traction across the company's portfolio of solutions and he views it as one of the best positioned vendors to execute on an integrated security platform story. 4. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying organic growth is likely to be better than forecast in the third quarter. 5. McKesson (MCK) upgraded to Outperform from Market Perform at Cowen with analyst Charles Rhyee saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/17
COWN
10/10/17
UPGRADE
Target $189
COWN
Outperform
McKesson upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rhyee upgraded McKesson (MCK) to Outperform saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. Distributor stocks, historically, fare very well coming out of a business model transition, Rhyee tells investors in a research note. He raised his price target for the shares to $189 from $176. The analyst this morning also upgraded AmerisourceBergen (ABC) to Outperform. Rhyee prefers both McKesson and AmerisourceBergen over Market Perform-rated Cardinal Health (CAH). He lowered his price target for the latter to $74 from $77.
NAVB Navidea
$0.43

-0.0016 (-0.37%)

NVS Novartis
$82.39

-1.11 (-1.33%)

10/25/17
LEHM
10/25/17
DOWNGRADE
LEHM
Underweight
Novartis downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis downgraded Novartis to Underweight and cut his price target for the shares to CHF 75 from CHF 80. Following the Q3 results, the analyst believes Entresto estimates remain too high and that competitive pressure increasing for Cosentyx. He sees a lack of catalysts in the near-term beyond RTH258.
10/20/17
10/20/17
DOWNGRADE
Target $0.9

Hold
Durect downgraded to Hold on 'major disappointment' of Posimir failure at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Durect (DRRX) to Hold from Buy, calling the fact that the company's Phase 3 Posimir trial in post-surgical pain did not meet its primary efficacy endpoint a "major disappointment." He has removed all Posimir revenue from his model and expects Novartis' (NVS) Sandoz will end the Posimir partnership. Walsh lowered his price target to 90c from $3.00 on Durect shares, which are down 55% to 87c in pre-market trading.
10/30/17
JMPS
10/30/17
DOWNGRADE
JMPS
Market Perform
Advanced Accelerator downgraded to Market Perform at JMP Securities
JMP Securities analyst Michael King downgraded Advanced Accelerator (AAAP) to Market Perform from Outperform saying a competing takeover bid to Novartis' (NVS) is unlikely.
OPHM OraPharma

PFE Pfizer
$35.36

0.04 (0.11%)

10/11/17
DBAB
10/11/17
NO CHANGE
Target $38
DBAB
Buy
Pfizer sale of consumer unit most likely option, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert believes a sale of Pfizer's Consumer Healthcare unit is the most likely outcome of the company's strategic review process. The analyst says he wouldn't be surprised if Pfizer has already received indications of interest in the business. A sale of the unit could be 3%-4% accretive depending on the price and assuming the company uses the proceeds to repurchase shares in order to offset dilution, Gilbert tells investors in a research note. He likes that management continues to explore strategic alternatives to increase shareholder value and keeps a Buy rating on Pfizer with a $38 price target.
11/01/17
UBSW
11/01/17
NO CHANGE
Target $38
UBSW
Buy
Pfizer risk/reward remains favorable, says UBS
UBS analyst Marc Goodman said he continues to like Pfizer's risk/reward following its Q3 results. The analyst believes the company could unlock some value with potential strategic action on its consumer business and also thinks its pipeline gets minimal credit. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/12/17
DADA
10/12/17
NO CHANGE
Target $79
DADA
Buy
Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson
DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.
QDEL Quidel
$37.66

-1.04 (-2.69%)

07/18/17
ADAM
07/18/17
UPGRADE
Target $42
ADAM
Buy
Quidel upgraded to Buy from Hold at Canaccord
Canaccord analyst Mark Massaro upgraded Quidel (QDEL) to Buy from Hold as it is a beneficial buyer of Alere (ALR) assets. The analyst said the deal doubles the company's revenues, is immediately accretive, was bought at a low multiple to market value, and provides the company with new platforms to add tests on. Massaro raised his price target to $42 from $25 on Quidel shares.
07/18/17
WBLR
07/18/17
UPGRADE
WBLR
Outperform
Quidel upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Weinstein upgraded Quidel to Outperform following the company's acquisition of Alere's Triage assets. Canaccord Genuity this morning also upgraded the shares.
09/19/17
LEHM
09/19/17
NO CHANGE
Target $45
LEHM
Overweight
Quidel price target raised to $45 from $39 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel shares to $45 citing improved accretion and visibility following the company's amended agreement to acquire the Triage and BNP businesses. The analyst continues to support the acquisition and keeps an Overweight rating on Quidel. Piper Jaffray this morning upgraded the shares.
09/19/17
PIPR
09/19/17
UPGRADE
Target $50
PIPR
Overweight
Quidel upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Quidel (QDEL) to Overweight and raised his price target for the shares to $50 from $35. The stock can continue to rise as investors digest how accretive the updated Alere (ALR) deal is and become more comfortable with an Abbott (ABT)/Alere deal close, Quirk tells investors in a research note. To reflect the amended deal agreement, the analyst raised his 2018 earnings estimates for Quidel by 64%.
REGN Regeneron
$404.39

-2.24 (-0.55%)

11/03/17
BARD
11/03/17
UPGRADE
BARD
Neutral
Regeneron upgraded to Neutral from Underperform at Baird
11/03/17
BARD
11/03/17
UPGRADE
Target $408
BARD
Neutral
Regeneron upgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney upgraded Regeneron to Neutral from Underperform based on better than expected Dupixent sales. The analyst said he even though he continues to believe competitive pressures threaten out-year estimates for the franchise, near-term estimates look achievable. Skorney has a $408 price target on Regeneron shares.
11/02/17
PIPR
11/02/17
NO CHANGE
Target $540
PIPR
Overweight
Sanofi's Dupixent sales in Q3 'crushed it,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says Sanofi's (SNY) revenue numbers this morning for Dupixent came in well ahead of anyone's expectations. Worldwide Dupixent sales of $87M "crushed it" versus the consensus of $70M and Piper's estimate of $82M, Raymond tells investors in a research note on Regeneron Pharmaceuticals (REGN). The launch continues to show strength, the analyst contends. He has an Overweight rating on Regeneron with a $540 price target.
11/03/17
11/03/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Buy from Hold at Argus with analyst Jim Kelleher citing an increase in user engagement, strong growth in adjusted EBITDA, and anticipated return to annual revenue growth next year. 2. Mattel (MAT) upgraded to Neutral from Underperform at DA Davidson with analyst Linda Bolton Weiser saying while the company suspended its dividend and saw a 51% decline in operating profit, she is positive on the company's 2-year $650M cost reduction program and plans to reduce its product range. 3. Wingstop (WING) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying he thinks the consensus 2018 same-restaurant sales projection of 3% growth will prove conservative. 4. CACI (CACI) upgraded to Buy from Hold at Noble Financial with the firm's analyst saying the market overreacted to bookings and pipeline news, and views the pullback as a buying opportunity. 5. Regeneron (REGN) upgraded to Neutral from Underperform at Baird with analyst Brian Skorney citing better than expected Dupixent sales. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$45.58

-0.49 (-1.06%)

10/31/17
NOMU
10/31/17
NO CHANGE
Target $31
NOMU
Buy
Sanofi opting out more valuable option for Voyager, says Nomura
Nomura Instinet analyst Christopher Marai says Sanofi-Genzyme (SNY) not opting into the outside U.S. development of Voyager Therapeutics's (VYGR) VY-AADC PD program is the more valuable of two possible outcomes for shareholders. Voyager consequently gains the worldwide rights to its compound, Marai tells investors in a research note. He points out that he did not model an ex-US collaboration and that the remaining Sanofi collaboration remains in place. Voyager's pipeline offers "potentially significant upside" to the shares with the translation of pre-clinical to clinical data points, Marai contends. He keeps a Buy rating on the shares with a $31 price target. The stock last night traded down 10% to $20.50.
10/31/17
ADAM
10/31/17
NO CHANGE
Target $35
ADAM
Buy
Voyager Therapeutics buy thesis based on standalone value, says Canaccord
Canaccord analyst Sumant Kulkarni noted Sanofi (SNY) decided not to exercise its ex-U.S. rights to Voyager Therapeutics' (VYGR) gene therapy candidate for advanced Parkinson's disease. The analyst believes the U.S. market is more valuable and he based his Buy thesis on the company's standalone value. He still likes Voyager shares despite Sanofi's decision and views any pullback as a buying opportunity. Kulkarni reiterated his Buy rating and $35 price target on Voyager Therapeutics shares.
10/31/17
WEDB
10/31/17
NO CHANGE
Target $31
WEDB
Outperform
Voyager Therapeutics price target lowered to $31 from $36 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Voyager (VYGR) to $31 from $36 following Sanofi's (SNY) decision to not opt-in ex-U.S. rights to VY-AADC, despite positive Phase 1 experience, which he views as an assessment of commercial opportunity for gene therapies outside U.S., rather than a reflection of VY-AADC's clinical profile. The analyst expects Voyager to carry VY-AADC to registration in ex-U.S. regions without a partner, although resources will likely be focused on opportunity in U.S. where a stronger reimbursement environment exists. Nierengarten continues to see Voyager shares as undervalued, and reiterates an Outperform rating on the stock.
ZYNE Zynerba
$10.83

-0.36 (-3.22%)

09/29/17
09/29/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Southern Company (SO) upgraded to Outperform from Sector Perform at RBC Capital with analyst Shelby Tucker is increasingly convinced that the regulators are "committed to completing" the company's Vogtle project. 2. Conn's (CONN) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the company's credit business, under new CEO Norm Miller, is "on a much more solid footing, and supportive of a return to expansion in retail." 3. Raytheon (RTN) upgraded to Buy from Hold at Deutsche Bank with analyst Myles Walton saying Raytheon is the most exposed to missile defense trends. 4. USA Truck (USAK), J.B. Hunt (JBHT), and Heartland Express (HTLD) were upgraded to Buy from Hold at Stifel. 5. Zynerba (ZYNE) upgraded to Overweight from Neutral at Piper Jaffray analyst Charles Duncan saying without over-interpreting the results from this "modest open-label program," the data establish an "activity signal and tolerability profile that merits further placebo-controlled study." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
CANT
10/02/17
UPGRADE
Target $17
CANT
Overweight
Zynerba upgraded to Overweight with $17 target at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $17 from $4. Following the positive Phase 2 Fragile X syndrome results, the analyst is encouraged by the potential for ZYN002 to treat the disease. Piros' model for the indication ascribes a 30% probability of success for ZYN002, with a peak sales opportunity of $1.5B.
09/29/17
PIPR
09/29/17
UPGRADE
Target $16
PIPR
Overweight
Piper Jaffray upgrades Zynerba on 'encouraging' Fragile X data
Piper Jaffray analyst Charles Duncan last night upgraded Zynerba Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $16 from $7. The stock closed yesterday up 52%, or $3.25, to $9.44 after the company announced positive data from its pilot study of ZYN002 in Fragile X. Without over-interpreting the results from this "modest open-label program," the data establish an "activity signal and tolerability profile that merits further placebo-controlled study," Duncan tells investors in a research note partially titled" Fragile but Encouraging". He believes similar efficacy in a Phase II/III program, planned to begin mid-2018, would make ZYN002 clinically valuable to Fragile X patients and caregivers, and potentially supportive of approval.
10/02/17
CANT
10/02/17
UPGRADE
CANT
Overweight
Zynerba upgraded to Overweight from Neutral at Cantor Fitzgerald

TODAY'S FREE FLY STORIES

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.